Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus

Journal of Virology

Volumn 83, Issue 23, 2009, Pages 12601-12610

  Kohlmann, Rebekka ^a   Schwannecke, Sarah ^a   Tippler, Bettina ^a   Ternette, Nicola ^a,b   Temchura, Vladimir V ^a   Tenbusch, Matthias ^a   Überla, Klaus ^a   Grunwald, Thomas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADENOVIRUS VECTOR F VACCINE; ADENOVIRUS VECTOR FSOL VACCINE; COMPLEMENTARY DNA; F PROTEIN; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; FEMALE; GENE CONSTRUCT; GENETIC CODE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOCYTOCHEMISTRY; IMMUNOGENICITY; LUNG HOMOGENATE; LUNG LAVAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS LOAD; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CODON; FEMALE; GENETIC VECTORS; LUNG; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 70450202778     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01036-09     Document Type: Article

References (61)

1. Alwan, W. H., F. M. Record, and P. J. Openshaw. 1993. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J. Immunol. 150:5211-5218.
2. Arnold, R., F. Werner, B. Humbert, H. Werchau, and W. König. 1994. Effect of respiratory syncytial virus-antibody complexes on cytokine (IL-8, IL-6, TNF-α) release and respiratory burst in human granulocytes. Immunology 82:184-191. (Pubitemid 24241730)
3. Barouch, D. H., M. G. Pau, J. H. Custers, W. Koudstaal, S. Kostense, M. J. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, B. Korioth-Schmitz, M. H. Newberg, D. A. Gorgone, M. A. Lifton, D. L. Panicali, G. J. Nabel, N. L. Letvin, and J. Goudsmit. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
4. Bembridge, G. P., J. A. Lopez, R. Bustos, J. A. Melero, R. Cook, H. Mason, and G. Taylor. 1999. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. J. Virol. 73:10086-10094.
5. Bembridge, G. P., N. Rodriguez, R. Garcia-Beato, C. Nicolson, J. A. Melero, and G. Taylor. 2000. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J. Gen. Virol. 81:2519-2523.
6. Bennett, N., J. Ellis, C. Bonville, H. Rosenberg, and J. Domachowske. 2007. Immunization strategies for the prevention of pneumovirus infections. Expert Rev. Vaccines 6:169-182. (Pubitemid 46607453)
7. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
8. Delgado, M. F., S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, J. Ravetch, J. A. Melero, P. M. Irusta, and F. P. Polack. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41.
9. DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
10. Eckardt-Michel, J., M. Lorek, D. Baxmann, T. Grunwald, G. M. Keil, and G. Zimmer. 2008. The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis. J. Virol. 82:3236-3249.
11. Falsey, A. R., P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759.
12. Fouillard, L., L. Mouthon, J. P. Laporte, F. Isnard, J. Stachowiak, M. Aoudjhane, J. C. Lucet, M. Wolf, F. Bricourt, L. Douay, M. Lopez, C. Marche, A. Najman, and N. C. Gorin. 1992. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant. 9:97-100.
13. Fu, Y., J. He, X. Zheng, Q. Wu, M. Zhang, X. Wang, Y. Wang, C. Xie, Q. Tang, W. Wei, M. Wang, J. Song, J. Qu, Y. Zhang, X. Wang, and T. Hong. 2009. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem. Biophys. Res. Commun. 381:528-532.
14. Glezen, W. P., S. B. Greenberg, R. L. Atmar, P. A. Piedra, and R. B. Couch. 2000. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283:499-505.
15. Graham, B. S., G. S. Henderson, Y. W. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
16. Grimaldi, M., B. Gouyon, P. Sagot, C. Quantin, F. Huet, J. B. Gouyon, and the Burgundy Perinatal Network. 2007. Palivizumab efficacy in preterm infants with gestational age ≤30 weeks without bronchopulmonary dysplasia. Pediatr. Pulmonol. 42:189-192.
17. Gupta, C. K., J. Leszczynski, R. K. Gupta, and G. R. Siber. 1996. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14:1417-1420.
18. Hallak, L. K., P. L. Collins, W. Knudson, and M. E. Peeples. 2000. Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:264-275.
19. Hancock, G. E., D. J. Speelman, K. Heers, E. Bortell, J. Smith, and C. Cosco. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
20. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509-2514.
21. Henrickson, K. J., S. Hoover, K. S. Kehl, and W. Hua. 2004. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr. Infect. Dis. J. 23:S11-S18.
22. Hsu, K. H., M. D. Lubeck, A. R. Davis, R. A. Bhat, B. H. Selling, B. M. Bhat, S. Mizutani, B. R. Murphy, P. L. Collins, R. M. Chanock, and P. P. Hung. 1992. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect. Dis. 166:769-775.
23. Hsu, K. H., M. D. Lubeck, B. M. Bhat, R. A. Bhat, B. Kostek, B. H. Selling, S. Mizutani, A. R. Davis, and P. P. Hung. 1994. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 12:607-612.
24. Imler, J. L. 1995. Adenovirus vectors as recombinant viral vaccines. Vaccine 13:1143-1151.
25. Impact Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537. (Pubitemid 28409250)
26. Johnson, P. R., and P. L. Collins. 1988. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J. Gen. Virol. 69:2623-2628.
27. Johnson, T. R., M. N. Teng, P. L. Collins, and B. S. Graham. 2004. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78:6024-6032. (Pubitemid 38661690)
28. Jung, T., U. Schauer, C. Heusser, C. Neumann, and C. Rieger. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods 159:197-207. (Pubitemid 23071909)
29. Kim, H., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
30. Kuate, S., D. Stefanou, D. Hoffmann, O. Wildner, and K. Uberla. 2004. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses. J. Gene Med. 6:1197-1205. (Pubitemid 40228131)
31. Li, X., S. Sambhara, C. X. Li, M. Ewasyshyn, M. Parrington, J. Caterini, O. James, G. Cates, R. P. Du, and M. Klein. 1998. Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188:681-688.
32. Liniger, M., A. Zuniga, and H. Y. Naim. 2007. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6:255-266. (Pubitemid 46613525)
33. McCoy, K., N. Tatsis, B. Korioth-Schmitz, M. O. Lasaro, S. E. Hensley, S. W. Lin, Y. Li, W. Giles-Davis, A. Cun, D. Zhou, Z. Xiang, N. L. Letvin, and H. C. Ertl. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604. (Pubitemid 46878063)
34. Moghaddam, A., W. Olszewska, B. Wang, J. S. Tregoning, R. Helson, Q. J. Sattentau, and P. J. Openshaw. 2006. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12:905-907.
35. Openshaw, P. J., F. J. Culley, and W. Olszewska. 2001. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20:S27-S31.
36. Openshaw, P. J., G. S. Dean, and F. J. Culley. 2003. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr. Infect. Dis. J. 22:S58-S64.
37. Pemberton, R. M., M. J. Cannon, P. J. Openshaw, L. A. Ball, G. W. Wertz, and B. A. Askonas. 1987. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J. Gen. Virol. 68:2177-2182.
38. Potthoff, A., S. Schwannecke, G. Nabi, D. Hoffmann, T. Grunwald, O. Wildner, N. H. Brockmeyer, K. Uberla, and M. Tenbusch. 2009. Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines. Vaccine 27:2768-2774.
39. Raboni, S. M., M. B. Nogueira, L. R. Tsuchiya, G. A. Takahashi, L. A. Pereira, R. Pasquini, and M. M. Siqueira. 2003. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 76:142-146. (Pubitemid 36880830)
40. Santosuosso, M., S. McCormick, and Z. Xing. 2005. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral. Immunol. 18:283-291.
41. Schauer, U., S. Hoffjan, J. Bittscheidt, A. Köchling, S. Hemmis, S. Bongartz, and V. Stephan. 2002. RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur. Respir. J. 20:1277-1283.
42. Schwarze, J., G. Cieslewicz, A. Joetham, T. Ikemura, M. J. Mäkelä, A. Dakhama, L. D. Shultz, M. C. Lamers, and E. W. Gelfand. 2000. Critical roles for interleukin-4 and interleukin-5 during respiratory syncytial virus infection in the development of airway hyperresponsiveness after airway sensitization. Am. J. Respir. Crit. Care Med. 162:380-386.
43. Sigurs, N. 2001. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. 163:S2-S6.
44. Simmons, C. P., T. Hussell, T. Sparer, G. Walzl, P. Openshaw, and G. Dougan. 2001. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J. Immunol. 166:1106-1113.
45. Simoes, E. A., and X. Carbonell-Estrany. 2003. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr. Infect. Dis. J. 22:S13-S18.
46. Simon, A., R. A. Ammann, A. Wilkesmann, A. M. Eis-Hübinger, O. Schildgen, E. Weimann, H. U. Peltner, P. Seiffert, A. Süss-Grafeo, J. R. Groothuis, J. Liese, R. Pallacks, and A. Müller: DSM RSV Paed. Study Group. 2007. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur. J. Pediatr. 166:1273-1283.
47. Souza, A. P., L. Haut, A. Reyes-Sandoval, and A. R. Pinto. 2005. Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res. 38:509-522.
48. Sullivan, N. J., T. W. Geisbert, J. B. Geisbert, D. J. Shedlock, L. Xu, L. Lamoreaux, J. H. Custers, P. M. Popernack, Z. Y. Yang, M. G. Pau, M. Roederer, R. A. Koup, J. Goudsmit, P. B. Jahrling, and G. J. Nabel. 2006. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS. Med. 3:e177.
49. Swenson, D. L., D. Wang, M. Luo, K. L. Warfield, J. Woraratanadharm, D. H. Holman, J. Y. Dong, and W. D. Pratt. 2008. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 15:460-467.
50. Tang, R. S., M. MacPhail, J. H. Schickli, J. Kaur, C. L. Robinson, H. A. Lawlor, J. M. Guzzetta, R. R. Spaete, and A. A. Haller. 2004. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol. 78:11198-11207.
51. Tatsis, N., and H. C. Ertl. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10:616-629.
52. Ternette, N., B. Tippler, K. Uberla, and T. Grunwald. 2007. Immunogenicity and efficacy of codon-optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25:7271-7279. (Pubitemid 47464663)
53. Ternette, N., D. Stefanou, S. Kuate, K. Uberla, and T. Grunwald. 2007. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol. J. 4:51. (Pubitemid 46945326)
54. van Elden, L. J., A. M. van Loon, A. van der Beek, K. A. Hendriksen, A. I. Hoepelman, M. G. van Kraaij, P. Schipper, and M. Nijhuis. 2003. Applicability of a real-time quantitative PCR assay for diagnosis of respiratory syncytial virus infection in immunocompromised adults. J. Clin. Microbiol. 41:4378-4381.
55. Van Kampen, K. R., Z. Shi, P. Gao, J. Zhang, K. W. Foster, D. T. Chen, D. Marks, C. A. Elmets, and D. C. Tang. 2005. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23:1029-1036.
56. Walsh, E. E., A. R. Falsey, and P. A. Hennessey. 1999. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am. J. Respir. Crit. Care Med. 160:791-795.
57. Waris, M. E., C. Tsou, D. D. Erdman, D. B. Day, and L. J. Anderson. 1997. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J. Virol. 71:6935-6939.
58. Weber, E., B. Humbert, H. J. Streckert, and H. Werchau. 1995. Nonstructural protein 2 (NS2) of respiratory syncytial virus (RSV) detected by an antipeptide serum. Respiration 62:27-33.
59. Welliver, R. C. 1995. RSV and chronic asthma. Lancet 346:789-790.
60. Xiang, Z. Q., G. P. Gao, A. Reyes-Sandoval, Y. Li, J. M. Wilson, and H. C. Ertl. 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77:10780-10789.
61. Yu, J. R., S. Kim, J. B. Lee, and J. Chang. 2008. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82:2350-2357.